As such, monoclonal antibodies that inhibit the activity of IL-17A and IL-17RA, the receptor for IL-17A and IL-17F, are US FDA-approved drugs for plaque psoriasis and other autoimmune disorders8. This evidence concerns the gene IL17A and psoriasis vulgaris.